HRTX supply chain intelligence for Heron Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CPIX | Cumberland Pharmaceuticals Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| CPIX | Cumberland Pharmaceuticals Inc. | 72% | Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX g… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological a… |
| MRK | Merck & Co., Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| ORANY | ORANY | 72% | that we have effective internal control over our financial reporting, investors could lose confidence in the reliability of our financial statements. Failure to comply with reporting requirements cou… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from HRTX graph: that we have effective internal control over our financial reporting, investors could lose confidence in the reliabi… |
| PCRX | Pacira BioSciences, Inc. | 72% | Reciprocal relationship from PCRX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from PCRX g… |
| PCRX | Pacira BioSciences, Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CPIX | Cumberland Pharmaceuticals Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| CPIX | Cumberland Pharmaceuticals Inc. | 72% | Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological … |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX graph: to register for resale 12.4 million shares of our common stock underlying the Senior Convertible Notes, including the… |
| HTGC | Hercules Capital, Inc. | 72% | to register for resale 12.4 million shares of our common stock underlying the Senior Convertible Notes, including the maximum number of shares of common stock issuable under the make-whole premium. T… |
| MRK | Merck & Co., Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological a… |
| PCRX | Pacira BioSciences, Inc. | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| PCRX | Pacira BioSciences, Inc. | 72% | Reciprocal relationship from PCRX graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from TKPH… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal therapy can be delivered with a sin… |
| FRESENIUS-KABI-USA-LLC | FRESENIUS-KABI-USA-LLC | 62% | ntial risks and needs for additional manufacturers and other suppliers for the manufacturing of our Products. Establishing additional or replacement suppliers for certain raw materials in our proprie… |
| INNOCOLL-PHARMACEUTICALS-LIMITED | INNOCOLL-PHARMACEUTICALS-LIMITED | 62% | ntial risks and needs for additional manufacturers and other suppliers for the manufacturing of our Products. Establishing additional or replacement suppliers for certain raw materials in our proprie… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HRTX-DEBT-10080 | Warrants outstanding: 220164 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| HRTX-DEBT | Debt stack $141.6M | 90% | Market cache reports total debt of $141.6M. |
| HRTX-DEBT-10081 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HRTX-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP | Rubric Capital Management LP | 90% | 13F overlay lists Rubric Capital Management LP as top holder; 169 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALT | Altimmune, Inc. | 100.00 | 2 | |
| CMPS | COMPASS Pathways plc | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| SVRA | Savara Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ALEC | Alector, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['supplier'] |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 |